论文部分内容阅读
氨甲喋呤(简称MTX)自1949年应用临床以来,它的用量、用法及抗瘤谱在不断地变化。1967年Djerassi在临床应用大剂量氨甲喋呤和甲酰四氢叶酸钙解救(简称HD-MTX-G FR)治疗恶性肿瘤,取得较好的疗效。尤其是成骨肉瘤截肢术后辅助这样的治疗,使预后大为改观,因此HD-MTX-CFR被认为是恶性肿瘤化学治疗的重大进展之一,逐渐用以治疗各种肿瘤。近年来不同作者对本疗法的临床评价分歧很大,甚至完全相反。本文报告我院1980年5月——1982年12月应用HD-MTX-CFR治疗恶性肿瘤32例,并对有关问题进行简要讨论。
Methotrexate (MTX) since its clinical application in 1949, its dosage, usage and anti-tumor spectrum is constantly changing. 1967 Djerassi in the clinical application of high-dose methotrexate and leucovorin rescue (referred to as HD-MTX-G FR) treatment of malignant tumors, and achieved good results. In particular, osteosarcoma amputation post-amputation such treatment, the prognosis has greatly improved, so HD-MTX-CFR is considered as one of the major advances in the chemotherapy of malignant tumors, gradually used to treat various tumors. In recent years, different authors have very different opinions on the clinical evaluation of this therapy, or even the exact opposite. This article reports our hospital from May 1980 - December 1982 application of HD-MTX-CFR treatment of 32 cases of malignant tumors, and the related issues are briefly discussed.